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In order to better understand the process ofbone formation, both in health and
disease; it is necessary to understand the molecular and genetic mechanisms underlying
this process. The precise molecular events occurring during osteoblast differentiation are
not yet understood. Initial work in our lab on four lines of transgenic mice overexpressing
a dominant negative p20C/EBP/3 transgene has shown varying degrees of osteopenia
secondary to reduced bone formation. Recent work has demonstrated that at the cellular
level the p20C/EBP/3 transgene interferes with terminal osteoblast differentiation or
differentiated function. Gross observation of these transgenic mice reveals a reduced
body size with smaller and more brittle long bones. It was demonstrated that there were
alterations in osteoblastic marker gene expression with an overall increase in bone
sialoprotein expression and an overall decrease in osteocalcin and Co12.3 GFP
expression. It is important to note that these latter two markers are terminal markers of
osteoblast differentiation. (Figure 1) The increase in bone sialoprotein expression coupled
with a reduction in osteocalcin mRNA raises the possibility that there is a differentiation
bottleneck and an accumulation of cells expressing a pre-osteoblastic phenotype.
An overall decrease in Co12.3 GFP expression and intensity in vivo was also noted in
these transgenic lines. Furthermore, micro-computed tomography data showed that the
amount ofmineralized tissue present in WT femurs is about four times the amount found
in TG femurs. Also, the cortical thickness ofWT bones was shown to be about twice that
ofTG bones. These preliminary studies suggest that C/EBP transcription factors are
required either for osteoblast differentiation or for the maintenance of the differentiated
osteoblast phenotype. Since p20C/EBP/3 is a dominant negative inhibitor of C/EBP
transcription factors that can heterodimerize with other C/EBP family members, it is not
yet clear which C/EBP transcription factors are required for osteoblast differentiation and
function. As a first step toward understanding the role of C/EBP’s during osteoblast
differentiation, the expression levels of endogenous C/EBP proteins during differentiation
ofprimary osteoblastic cells were determined. It is critical to assess C/EBP expression at
the protein level, since multiple protein isoforms of several members of the C/EBP
family, including C/EBPcz and C/EBPI3, can be generated from a single mRNA species
by differential translation. It is important to note that these isoforms are functionally
distinct. Truncated members of the family, such as p20C/EBPI3, lack transactivation
domains but can still dimerize with full-length isoforms, thereby inhibiting their function.
It was essential to identify molecular targets ofp20C/EBP/3 that might be involved in
inhibiting osteoblast differentiation in the transgenic mice. This inhibition can occur
either by regulating the expression levels of these molecular targets or by altering their
function via direct interaction with p20C/EBP/3. To identify the molecular targets of
p20C/EBP/3, the varying levels of C/EBPI3 and other various proteins during osteoblast
differentiation were determined via western blot analysis. Factors that are known to
interact with C/EBP/3 via dimerization or other types ofprotein-protein interactions
include all members ofthe C/EBP family, other bZip transcription factors such as
ATF/CREB, as well factors outside the bZip family such as Runx2. These objectives will
help to better understand the role of C/EBP’s in osteoblast differentiation and provide
some insight into how the p20C/EBP/3 transgene is affecting the path of osteoblast
differentiation.
Background
Osteoblasts are the primary bone-forming cells in the body. Their presence and
activity are essential for acquiring and maintaining normal bone mass. It is likely that
impaired generation ofbone cells, either due to an underperforming lineage or to a
diversion of the lineage to other cell types, may be a primary cause for diminished bone
mass. 1] Identifying factors that regulate osteoblast differentiation will be necessary to
understand diseases ofbone and to designing effective anabolic therapeutic strategies. [1]
Osteoblast precursors are recruited from a multipotential mesenchymal progenitor
that can give rise to several differentiated cell phenotypes including fibroblasts,
chondrocytes, adipocytes and osteoblasts. [1] (Figure 2) Undifferentiated
osteoprogenitors are present in the bone marrow and periosteum. [2] These
undifferentiated osteoprogenitor cells eventually differentiate into preosteoblasts,
osteoblasts, and finally osteocytes. (Figure 3) The differentiation and ultimate fate of
these osteoprogenitor cells is determined and influenced by a complex and still poorly
understood interaction ofhormones and local factors.
Previous analysis of C/EBP/3 null mice has demonstrated a role for this protein in
establishing the differentiated phenotypes of several cell types including myeloid cells,
hepatocytes, adipocytes, ovarian granulosa cells, mammary epithelial cells and
keratinocytes. [3] Preliminary work in our laboratory has also suggested an important
role for C/EBP family members in growth and differentiation of ostoeblasts. There exist
some discrepancies in the literature regarding the expression pattern of C/EBP
transcription factors during osteogenic differentiation. Iyer et al, using the murine
MC3T3-E 1 osteoblast model, reported that C/EBP/3 protein levels and DNA binding
activity were high in proliferating cells but decreased during differentiation. [4] They
found that constitutive expression of full length C/EBP/3 increased proliferation and
prevented differentiation. In contrast to these findings, Gutierrez et al. found that in
primary rat osteoblast cultures, C/EBP/3 and C/EBP6 are abundantly expressed in
proliferating cells, decline during the mid-stage of differentiation, and then subsequently
increase at late stages of differentiation. [5] C/EBP/3 and C/EBP6 have also been shown
to act synergistically with Runx2 (also known as Cbfal), a transcription factor and
nuclear matrix binding protein required for osteogenic differentiation, to enhance
osteocalcin transcription in cell culture systems. [5] The Runt-related transcription factors
are important gene regulatory proteins that control cell lineage differentiation in
osteogenesis. These transcription factors are essential for cellular differentiation and fetal
development. Truncations involving the C-terminus ofthese factors result in lethal
skeletal phenotypes and eliminate the targeting of these factors to foci within the sub-
nucleus [6]. Correlating C/EBP/3 and 6 function with Runx2/Cbfal presents a critical link
between C/EBP factors and osteoblast differentiation given that Runx2/Cbfal is essential
for osteoblast responses to extracellular matrix signals and required for the expression of
genes associated with osteoblast differentiation. [4] Several key studies have established
that Runx2/Cbfal is required for both in vivo bone formation as well as for osteoblast
differentiation. [7] Runx2 has been seen to directly regulate osteoblast-specific genes
including osteocalcin, osteopontin, and type I collagen through its specific DNA binding
element, OSE2. [8] It has also been demonstrated that forced expression ofRunx2/Cbfal
in non-osteoblastic cells leads to osteoblast-specific gene expression. [9] Furthermore,
Runx2-defficient mice completely lack bone formation, due to an absence of osteoblasts,
demonstrating that Runx2 is an essential factor for osteoblast differentiation. 10]
Humans with cleidocranial dysplasia, an autosomal dominant condition characterized by
phenotypic changes in skeletal patterning and growth, have deletions within the human
Runx2/Cbfal gene. [11] The disease is characterized by defective endochondral and
intramembranous bone formation, disturbed skeletal development, hypoplastic or aplastic
clavicles, and patent fontanelles. [12]
The C/EBP family has been shown to play a vital role in regulating adipocyte
commitment, differentiation and gene expression. C/EBP/3 and C/EBP6 have been shown
to be expressed very early in the pathway from multi-potential progenitor cells to
adipocytes. [13] [14] C/EBP [ and 6, expressed early in the cascade, initially coordinate
the transcription of the C/EBPc gene. As C/EBP [3 and acquire DNA binding activity,
they become localized on the centromeric satellite DNA. C/EBPa later becomes
centromere-associated as the cells undergo terminal differentiation. [15] C/EBP/3 and
C/EBP6 therefore induce the expression of C/EBPa and PPAR3,, which direct the
expression of terminal adipocyte marker genes. 16] Disruption of the C/EBPc 15],
C/EBP/3 and C/EBP6 genes [17] prevented normal development of adipose tissue.
C/EBPot null mice show a block in terminal differentiation of adipocytes, while C/EBP/3
and C/EBP6 knockout mice show a reduced commitmem ofprogenitors to the adipocyte
lineage. The role of C/EBP transcription factors in adipogenesis may have important
implications for their role in osteoblast differentiation, since osteoblasts and adipocytes
are closely related cells that share a common pluripotent progenitor. Accelerated
adipogenesis in bone marrow is often observed in patients with osteoporosis in
association with bone loss. [18] Because osteoblasts are derived from the same
undifferentiated mesenchymal cells as adipocytes, it appears likely that a balance
between osteoblastogenesis and adipogenesis is critical to maintaining bone volume. The
role of C/EBP’s in adipogenesis may therefore provide some insight into their possible
roles in the regulation of osteogenesis.
CCAAT/Enhancer-Binding Proteins (C/EBP)
The C/EBP’s are a family of transcription factors that function in tissue
differentiation, healing, immune response and tissue metabolic functions. [19] There are
currently six members of the C/EBP family that have been isolated and characterized:
C/EBP
-a, -/3, -6,
-% -e, and -’. [20] The majority ofthem are expressed in liver, spleen
and adipocytic tissues. [5] The C/EBP’s are classified as members ofthe basic leucine
zipper (bZIP) transcription factor family. [21] They are structurally related to each other,
each consisting of an amino terminal transactivation region, a central basic DNA-binding
domain, and a COOH-terminal dimerization interface termed the leucine zipper segment.
[19]
The terminal leucine zipper mediates dimerization between C/EBP polypeptides.
This dimerization is required for DNA binding and for the activation of transcription in
target genes. [22] (Figure 4) C/EBP proteins can form either homodimers or heterodimers
with one another, as well as with other members ofthe bZIP family. They are also
capable ofprotein-protein interactions with non-bZIP transcription factors. [23] The
central DNA binding domain is highly conserved and rich in basic amino acids. The
amino-terminal region has amino acid sequences that are unique to each C/EBP member
and are critical for transcriptional activity.
C/EBP/3 mRNA has three in-frame AUG start codons which initiate the
translation of three protein isoforms: 38kDa, 35kDa and 20kDa. [4] (Figure 5) The larger
products, p38 and p35C/EBP/3 (originally called LAP) contain the N-terminal
transactivation domain and function as transcriptional activators. [24] The 38 kDa
C/EBP3 isoform, initiating at the upstream in-frame AUG codon, is expressed at much
lower levels than the 35kDa protein.[3] The 20 kDa isoform (originally LIP) lacks the N-
terminal transactivation domain but contains the C-terminal bZIP domain. P20C/EBP/3
therefore acts as a dominant negative regulator of C/EBP function. [25] This isoform can
also arise by a proteolytic cleavage of full length C/EBP/3 that is C/EBPc independent.
[26] Another study noted that p20 and p14 C/EBP/3 isoforms, both lacking the N-terminal
transactivation domains, can be generated by artifactual proteolysis of full-length
C/EBP/3 during preparation of nuclear extracts. [3] By comparing various extraction
procedures to analyze endogenous and over-expressed C/EBP/3 proteins, they determined
that p20C/EBP/3 is generated predominantly by in vitro proteolytic cleavage during
isolation from cells and that pl4C/EBP/3 is produced exclusively by this mechanism. [3]
In transfected cells, the full-length p34 and p38 isoforms were detectable in the
cytoplasm where translation occurs. The truncated p20 and p14 isoforms, however, were
not detectable in the cytoplasm, indicating that they are not primary translation products.
[3] Most literature, contrary to the study just discussed, show evidence for the synthesis
ofp20C/EBP/3 via alternative translation. These different sized polypeptides are produced
for C/EBP/3 by alternative use oftranslation initiation codons in the same mRNA
molecule due to a leaky ribosome scanning mechanism. [23] C/EBP/3 mRNA can
produce the three isoforms mentioned earlier, 38kDa, 35kDa and 20kDa, with the 35 and
20kDa isoforms being the major polypeptides produced in the cells. [25]
Ex Vivo Cell Cultures
Cell cultures allow researchers to study both the intrinsic functions of the cell,
such as proliferation, differentiation and matrix production, as well as the ability of cells
to interact with one another and the surrounding environment. There are two different
types of cell culture: primary cultures and permanent cell lines. Although permanent cell
lines can be conveniently purchased and maintained, several shortcomings exist with this
approach. Permanent osteoblastic cell lines can undergo alterations during passage which
may result in the loss or alteration of the phenotype. Also, they may possess limited
differentiation capacity. In order to conduct genetic studies on these models, gene transfer
approaches need to be used. The efficiency of gene transfer is not always complete and
can complicate interpretation.
Primary cells, unlike permanent cells, must be harvested fresh from the mouse in
order to be grown in culture. Primary cell cultures can be derived from either bone
marrow stromal or calvarial cell populations. Primary calvarial cultures have several
advantages over stromal cell cultures. They are more homogeneous and are capable of
producing more reproducible osteogenic differentiation. In addition, they allow cells
derived from genetically-manipulated mouse models to be studied in culture. It is for
these reasons that we chose to use the primary calvarial culture method for the present
studies.
Rationale
In order to better understand the process ofbone formation, it is necessary to
understand the molecular and genetic mechanisms underlying this process.
Unfortunately, the precise molecular events occurring during osteoblast differentiation
are not yet understood. Initial work in our lab on p20C/EBP/ transgenic mice has shown
a decrease in bone formation as well as a decrease in osteoblast formation, either due to a
decrease in the differentiation of osteoblasts or to a decreased function of the osteoblasts
formed. In the present study, we will measure C/EBP expression at the protein level
along with several potential targets of C/EBP action as a first step toward understanding
the molecular mechanisms of C/EBP function.
Hypothesis
1. C/EBPs are important determinants of osteoblast differentiation, therefore, the
levels of endogenous C/EBP proteins will be altered during the course of
osteoblast differentiation.
2. In our transgenic model, over-expression ofp20C/EBP inhibits osteoblast
differentiation or function via a physical interaction with endogenous
transcription factors.
Specific Aims
1. To determine the expression levels of endogenous C/EBP proteins during
osteoblast differentiation in primary osteoblast cultures. Key questions that we
hope to answer include:
Does the ratio ofp35/p20 C/EBPI3 change during osteoblast
differentiation?
Is C/EBPa expression increased during osteoblast differentiation as it
is during adipogenesis, suggesting a role in terminal differentiation?
Will changes be observed in the levels of other C/EBP family
members, such as C/EBP6, during osteoblast differentiation?
Does overexpression ofp20C/EBP/3 result in compensatory changes in
expression of endogenous C/EBP transcription factors?
2. To identify molecular targets ofp20C/EBP/3 that may be involved in the
inhibition of osteoblast differentiation in transgenic mice. This could occur either
by regulating their expression levels or by altering their function via direct
interaction with p20C/EBP/3.
Factors that are known to interact with C/EBP/via dimerization or other
types ofprotein-protein interactions include"
C/EBPs (p20C/EBP/3, p35C/EBP/3, C/EBPa, C/EBP6)
Other bZip transcription factors (Nrfl, ATF/CREB)
Factors outside the bZip family (Runx2)
10
Materials and Methods
Creation ofFLAG-tagged p20C/EBP/3 Transgenic Mice
The transgenic mice used in this project harbor an amino-terminal FLAG epitope
incorporated into a truncated p20C/EBP construct. (Figure 6) This truncated construct
was developed to inhibit the activity of endogenous C/EBP transcription factors in order
to better understand the role of C/EBPs in osteogenesis. Developing a truncated C/EBP/3
transgenic model avoids complications ofpossible redundancy between family members
and/or neonatal lethality associated with knock-out mouse models. The transgenic model
also limits mortality of the mice by using a specific construct to target the transgene to
limited distribution within the tissues. The pOBCol3.6 construct utilizes the Co13.6
promoter fragment of the Collal promoter that is preferentially expressed in bone, teeth,
skin, tendon and lung.
To identify the cells that express this C/EBP transgene, an amino-terminal FLAG
epitope was incorporated into the p20C/EBP/3 construct. The transgene protein can
subsequently be identified via a Western blot and immunocytochemistry using the M2
FLAG antibody. This allows us to distinguish the over-expressed p20C/EBP/3 isoform
from endogenous C/EBP isoforms. The dominant negative function ofp20C/EBP/3 is not
altered by the incorporation of the FLAG epitope due to the modular nature of
transcription factors.
The FLAG p20C/EBP[3 construct was prepared by PCR using the original CMV-
LIP plasmid as a template. It is 467 base pairs in size. This product was cloned into a
PCR3.1-Uni, a TA expression vector containing a CMV promoter for mammalian
expression and a T7 RNA polymerase site for in vitro translation. A series of
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experiments were performed to confirm that the FLAG-tagged p20C/EBP exhibits the
expected DNA binding, nuclear localization and dominant-negative function.
Targeting ofFLp20C/EBP/3 to osteoblastic cells:
A pOBCol3.6-FLp20/CEBP/3 construct was used to target expression of
FLp20C/EBP/3 throughout the osteoblastic lineage. PCR3.1-FLp20/CEBP/3 was digested
with HindIII and XbaI and the resulting FLp20/CEBP/3 fragment was subcloned into an
intermediate Cla vector which contains a polylinker and the bovine growth hormone
(bGH) polyadenylation sequence flanked by two ClaI sites. Following digestion of ClaI,
the FLp20/CEBP/%bGH cassette (792 bp) was isolated and subcloned into
pBCSK+ColInt5.2Xba, which contains a ClaI site downstream ofthe 3.6 kb Collal
promoter and 1.6 kb Collal first intron. Clones containing FLp20/CEBP/3 in the correct
orientation were identified using asymmetric restriction sites. The
pOBCol2.3FLp20/CEBP/3, which targets expression to more differentiated osteoblasts, is
prepared by subcloning the ClaI FLp20/CEBP/3-bGH cassette into an expression vector
which is identical to the pOBCol3.6FLp20/CEBP/3 construct, except that the Collal
promoter has been truncated to 2.3 kb.
Since there is differential use of Collal promoter elements as a cell progresses
through differentiation, FLp20C/EBP/3 expression can be targeted toward cells at
multiple stages ofthe osteoblast lineage, pOBCol3.6GFP expression has been reported in
early pluripotent progenitor cells as an early marker of the osteoblast lineage.
pOBco12.3GFP expression, on the other hand, is restricted to more differentiated
osteoblasts. A pOBCol3.6 construct was therefore used to target FLp20C/EBP/3
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expression broadly throughout the osteoblast lineage. Heterozygous transgenic and wild
type mice were crossed with homozygous pOBCol2.3 GFP reporter mice which provided
us with an osteoblast-specific marker, GFP, which will be discussed later.
Preparation of Transgenic FLp20C/EBP/30verexpressing Mice"
To prepare transgenic CD-1 mice that over express FLp20C/EBP/3, a pronuclear
microinjection technique ofpOBCol3.6-FLp20C/EBP/3 was used. Potential founders
were screened by dot-blot analysis of tail snip DNA using a probe directed against the
human growth hormone polyadenylation site, which was cloned downstream from
FLp20C/EBP. Mice that screened positive for the human growth hormone 3’-UTR were
confirmed by PCR using a 5’-primer directed against the Collal first intron (5’-
ACCCTCCTCCATTTTAGCC-3’) and a 3’-primer directed against the FLAG epitope
(5’-CATCGTCGTCGTCCTTCTAGTC-3’). Four transgenic founders (2 female, 2 male)
were obtained and bred with wild type CD-1 mice to establish transgenic lines. Progeny
were screened for the presence of the transgene at the time ofweaning by extracting tail
DNA and subsequent PCR amplification. The four transgenic lines are" 00-50-9, 00-50-
10, 00-63 and 00-65.
PCR Genotyping for Transgene Expression
Transgenic pOBCol3.6-FLp20C/EBP[ mice were crossed with homozygous
pOBCo12.3GFP mice. GFP is a fluorescent reporter, providing an osteoblast-specific
marker, which can be imaged in living cells in culture under a microscope. This will
13
allow the process of osteoblastic differentiation to be observed and quantitated in real
time.
Mouse tail genomic DNA was extracted using the Wizard genomic DNA
extraction kit (Promega, Madison, WI, USA). PCR genotyping was completed by using
primers corresponding to the first intron of rat CollA1 gene and the FLAG sequence
which generated a unique 700 base pair produce, characteristic of the transgene. PCR
cycles were" 94 degrees C, 30 seconds; 65 degrees Celsius, 30 seconds; 72 degrees
Celsius, 2 minutes. The cycle number was 32. PCR products were then fractionated
through gel electrophoresis on a 1% agarose gel in Ix TBE buffer and visualized by
ethidium bromide staining. Presence of the GFP transgene was assessed by the presence
of fluorescence under a UV light.
Primary Osteoblastic Cell Culture Model
Calvaria, comprising both frontal and parietal bones, were dissected from six to
eight week old wild type and pOBCol3.6-FLp20 C/EBP/3 transgenic mice. Both female
and male mice were used, with the sex ratio being held constant for wild-type and
transgenic groups. Once dissected, the calvaria were rinsed in PBS and placed in full
growth medium- Dulbecco’s modified Eagle Medium (DMEM)- supplemented with 10%
heat-inactivated fetal calf serum (HI-FCS), 100g/ml penicillin and 50g/ml streptomycin
(P/S). Through a series of five cellular digestions with a mixture of 1.5U/ml Collagenase-
P in PBS and 0.05% trypsin/lmM EDTA at 37% on a rocking platform, primary cells
were isolated. The first of five digestions was discarded. The remaining digests were
pooled once the osteoblasts were isolated. The digests were strained in a 40gm strainer
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and then centrifuged. The cell pellet was collected after centrifugation at 3000rpm for
two minutes and then re-suspended in DMEM, 10%FCS and P/S. After the primary cells
were isolated, the cell numbers were counted electronically using a Coulter Counter
(Coulter Corporation, Miami, USA). They were then plated in 8cm2 wells to a density of
17,500cells/cm2 for a total of 140,000 cells per well. The cultures were fed on the second
and fifth day with DMEM (Dulbecco’s modified Eagle Medium ) media supplemented
with 10% heat-inactivated fetal calf serum (HI-FCS), 100t/ml penicillin and 50t/ml
streptomycin (P/S). From day 7 through day 21, the cultures were fed every 48 hours
with alpha-MEM, 10% HI-FCS, penicillin (100U/ml), streptomycin (50ug/ml), and
supplemented with 50tg/ml phosphoascorbate and 4mM [-glycerol phosphate. The
osteogenic capacity of the cells were assessed via visualizing mineralized bone nodules
under a microscope and visualization of GFP fluorescent colonies by fluorimager and
fluorescence microscopy.
Imaging of Mineralized Colonies and GFP Fluorescent Colonies
Osteogenic cultures were examined and photographed on days 14, 17 and 21
using phase contrast and fluorescence microscopy. Additionally, the distribution and
quantification ofGFP expression in the cell cultures was observed at the macroscopic
level via fluorimaging.
GFP expression in cell-culture was visualized using an Olympus IX50 inverted
microscope with an IX-FLA inverted reflected light fluorescence (Olympus America,
Inc., Melville, NY, USA). Fluorescent images were visualized with GFP filters (exciter,
D500/20, dichroic, 525DCLP; emitter, D550/40) with equal exposure times. These
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images were recorded with a SPOT- camera (Diagnostic Instruments, Inc., Sterling
Heights, MI, USA). Both brightfield and fluorescent images were taken at equal exposure
times for all groups at a magnification of40x and 100x. The distribution and intensity of
GFP expression in cell culture was also recorded with a FluorImager SI (Molecular
Dynamics, Sunnyvale, CA, USA) using a 515-nm emission spectrum at PTM settings of
800. Images were recorded with ImageQuaNT software (Molecular Dynamics).
Whole Cell Extracts ofPrimary Cells in Culture
Whole cell extracts were obtained from cultured primary calvarial cells on day 14,
17 and 21 by the method ofZhon, et al. [20] Media was decanted from culture wells and
cells were rinsed with 2ml/well PBS at room temperature. The following steps were
performed on ice: 0.2ml RIPA buffer + Inhibitors were added to each well. RIPA buffer
consists of lx PBS, 1% Nonidet p-40, 0.5% sodium deoxycholate and 0.1% SDS.
Protease and phosphatase inhibitors were added fresh and included 10mg/ml PMSF,
10mg/ml aprotinin and 100mM sodium orthovanadate. The plates were rocked on ice for
15 minutes. The wells were then scraped and the lysate transferred to labeled 1.5ml
Eppendorftubes. The first well was then rewashed with 0.2 ml ofthe buffer mix which
was serially transferred to additional wells to maximize recoveries. The lysates were
combined and then lysed by passing through a 21 gauge needle six times at 4C in a cold
room. The cells were then microcentrifuged at 3000 RPM for 15 minutes at 4C. The
supematant was transferred to a fresh tube and the pellet discarded. The supematant was
then aliquotted to avoid repeated freeze-thaw cycles and stored at -80C for later use.
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BCA Protein Assays
In order to determine the amount ofprotein present in the primary extracts, a
BCA protein assay was performed in a 96 well dish against a standard curve using known
protein. (Figure 7)Both standards and samples were assayed in duplicate, thereby
reducing the error by averaging the two wells. Standard wells contained 5/xl of lysis
buffer, (the volume used for analysis extracts) 5 #1 of the appropriate standard and 190 #l
ofA + B solution from the BCA Protein Assay Kit (Pierce BCA Protein Assay Kit
Product #23228). Unknown samples contained 5 #1 of extract, 5 #1 ofwater and 190 #1 of
ofA + B solution. Samples were incubated at 60C for 30 minutes and assayed
colorimetrically on a plate reader (Bio-Rad model 680) at an absorbance of 490 nm.
Western Blot Analysis
Western blots were used to detect the presence of a specific protein in a cell lysate
or protein mixture using an antibody against that protein. The western blot protocol uses
the PAGE protocol which was adapted from "Current Protocols in Molecular Biology",
section 10.2. The first step of the western blot, which is completed the day before, was to
pour the separating gel. The acrylamide concentration is determined by the size of the
protein being detected. These proteins were then run on a polyacrylamide gel which
separates them based on molecular weight. For our protein of interest, including 20KDa
and 35KDa proteins, a 15% gel was used. The separating gel consisted of 7.5mls 30%
acrylamide: 0.8% bisacrylamide (37.5"1), 3.75mls 4x Tris-C1- pH 8.8, 3.75mls H20, 50 #1
10% ammonium persulfate and 10 #1 Temed. The gel was gently poured to avoid bubbles
and was subsequently overlayed with 20% ethanol for 90 minutes to allow
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polymerization. After rinsing the EtOH offwith deionized H20 and blotting dry with 3M
blotting paper, the gel was then overlayed with lxTris-C1/SDS- pH 8.8 and covered with
plastic wrap until the following day. The next day a 4% stacking gel was poured,
consisting of 0.65mls 30% acrylamide: 0.8% bisacrylamide (37.5"1), 1.25mls 4x Tris-
C1/SDS- pH 6.8, 3.05mls H20, 25/xl 10% ammonium persulfate and 5/xl Temed. After
the gel was gently poured, a 10 well comb was placed between the glass plates to create
the loading wells, the air bubbles were removed and polymerization was allowed to occur
for 1 hour. After polymerization, the gel was placed in a buffer tank (Bio-Rad Mini-
Protean 3 apparatus) and electrophoresis buffer was added to both the inner and lower
buffer chamber. The lx electrophoresis buffer consisted of 1.5g Tris Base, 72g Glycine,
5g SDS and q.s. to 1 liter with autoclaved H20.
The maximum volume ofthe loading wells was 50 #1. From previous
experiments, it was determined that the optimal concentration ofprotein required was 30
#g ofprotein. Based on the protein assay curve that was discussed above, the volume of
sample needed for 30/xg ofprotein was calculated. Samples were combined in individual
tubes with 6/xl loading buffer and lysis (RIPA) buffer was added to the samples to bring
them up to the volume of the most dilute sample. A positive control, if available for the
protein we were detecting, was always placed in loading lane 1 along with necessary
amounts loading buffer and lysis buffer. This was followed by the rainbow molecular
weight markers in lane 2. Wells 3-10 were loaded with the individual samples discussed
above and blank wells, if present, were loaded with loading buffer and lysis RIPA buffer
equating to the total volume loaded in the sample wells. This helped prevent irregularities
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in the gel ran. Prior to being loaded, all samples except rainbow markers were incubated
at 80C water for 4 minutes and then quick spun at room temperature for 10 seconds.
The electrophoresis gel is first mn at 60 volts for 45 minutes or until the rainbow
markers first begin to separate. The voltage was then increased to 150 for I hour or until
the orange marker, corresponding to 30KDa, reached the door of the gel unit. While the
gel was running, the PVDF membrane was cut to size and soaked in MeOH for 3 minutes
on a rocker. The MeOH was gradually replaced with water. The membrane was placed in
transfer buffer (6.06g Tris Base, 28.8g Glycine, 400mls MeOH q.s. to 2 liters with cold
H20, pH 8.3). When the gel finished running, glass plates were removed and the gel was
placed in transfer buffer. The transfer buffer unit was arranged as follows: White
plastic/anode, fiber sponge, Whatman 3MM paper, PVDF membrane, SDS-PAGE gel,
Whatman 3MM paper, fiber sponge, Black plastic/cathode. Bubbles were removed then
the unit was tightly placed into the transfer unit. The unit was filled with transfer buffer
and a stir bar placed at the bottom of the unit. Transfer was allowed to take place for 1
hour at 100V on ice.
When transfer was complete the PVDF membrane was trimmed and rocked for 1
hour in 25ml blocking buffer (lx TBS, 0.1% Tween-20 and 5% nonfat dry milk) at room
temperature. The membrane was washed 3 times in TBST (Ix TBS and 0.1% Tween-20)
for 5 minutes. The membrane was then placed in a plastic bag and incubated with a 1:200
dilution ofprimary antibody. The bag was tightly sealed and left on a rocker overnight in
the 4C cold room. The next morning the membrane was washed 3 times in TBST for 5
minutes. The membrane was incubated with HRP-conjugated secondary antibody (1:3000
dilution) on a rocker for 1 hour at room temperature. The membrane was then washed 3
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times in TBST for 5 minutes. To develop the western blot, the membrane was incubated
with 0.5ml 20x LumiGLO, 0.5ml 20x Peroxide and 9.0 ml Milli-Q water with gentle
agitation for I minute at room temperature. Excess developing solution was drained and
the membrane was placed between plastic sheets and exposed to x-ray film. Usual
exposure times were 30 seconds, 1 minute, 2 minutes, 5 minutes and overnight. Each
rainbow marker that is visualized on the membrane was marked on the developed film to
note the position ofmolecular weight markers.
Stripping a Western Blot
A membrane that has already been probed via a western blot may be stripped and
reprobed with a different antibody. After completion of a western blot, the blot was
sealed and stored in a plastic bag at 4C for later use. To strip a blot, it was first placed in
2ml of the following stripping solution: 100mM 2-mercaptoethanol, 2% SDS and 62.5
mM Tris-C1 pH 6.7. The blot was incubated in this solution in a sealed plastic container
in a shaking water bath at 50C for 30 minutes. The blot was then rinsed 3 times with
TBST at 5 minutes each. The blot is then reblocked with 25ml ofblocking buffer for 1
hour prior to reprobing with a new antibody.
Loading Controls
Tubulin, a 50 kilodalton cytoskeletal protein, was used as a loading control for the
western blots. The primary use of a loading control was to validate that the lanes in the
gel have been evenly loaded with the samples. This is an essential step in ensuring the
reliability of the data when comparing the expression levels of a protein in different
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samples. The various blots were stripped as described above and were subsequently
reprobed for tubulin.
Results
GFP Expression and Mineralization
Cell colonies in the primary osteoblastic calvarial cell cultures were examined
daily using phase contrast and fluorescent microscopy to visualize Col 2.3GFP
expression. The most representative areas were then imaged in real time on days 14, 17
and 21 in living cells cultured in tissue culture in plastic 6 well plates. Both phase and
fluorescent images were taken at equal exposure times for all groups at a magnification of
both 40x (Figure 8) and 100x (Figure 9). Additionally, the distribution and quantification
of GFP expression in the cell cultures was observed at the macroscopic level via
fluorimaging. (Figure10) GFP expression was found to initiate around day 10 in the wild-
type cultures and around day 12-14 in the transgenic cultures. At day 10 of observation,
the transgenic cells appeared denser and more elongated than the wild-type cells. It was
noted that the beginning formation ofnodules in both wild-type and transgenic wells
occurred around day 14. It was consistently observed that although the number of
transgenic colonies ultimately exhibiting GFP expression between wild-type and
transgenic mice was similar, both the intensity of GFP expression and the amount of
mineralization in transgenic cultures were decreased at coincident time points. This





To help follow the expression of the p20C/EBP/3 transgene in cells of the
osteoblast lineage, an amino-terminal FLAG epitope was incorporated into the
p20C/EBP/3 construct. Anti-FLAG is therefore specific for the presence of the transgenic
p20C/EBP/3 only. When probing these blots for FLAG, our transgene was evident
correlating to 20kDa bands in the transgenic lanes only. (Figure 11) As expected, the
wild-type lanes were blank at 20kDa, serving as a negative control for the presence of the
transgene. Several blots displayed various non-specific bands not relevant to the protein
of interest. The general consensus throughout the anti-FLAG blots was that
FLp20C/EBP/3 protein decreased over the time-points. This was unexpected because
pOBCol3.6GFP, which is driven by the same promoter as the transgene, comes on early
in the osteoblast lineage and stays equally present throughout terminal osteoblast
differentiation, pOBCol3.6GFP is usually expressed around day 7 at the multi-potential
precursor stage of the osteoblast lineage.[ 1] It was seen in our experiments that FLAG
came on between days 7 and 10 of the osteoblast lineage. Many blots probed for FLAG
were stripped and then re-probed with anti-C/EBP/3 to visualize the corresponding levels
ofp20C/EBP/3 in the transgenic cultures compared to endogenous levels ofp20C/EBP/3
in the wild-type cultures. (Figure 12) Anti-C/EBP/3 will detect both endogenous and
transgenic C/EBP/3. The general consensus in these stripped anti-C/EBP/3 blots showed
the levels ofboth endogenous and transgenic p20C/EBP/3 in the transgenic cultures to be
similar to the amount ofFLAG proteins present in the anti-FLAG blots. They also
seemed to decrease throughout the time-points as they did in the anti-FLAG blots.
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Unfortunately, due to possible sensitivity issues, there was no evidence of endogenous
p20C/EBP/3 in the wild-type cultures and the levels of endogenous full-length C/EBP/3
were not easily visible following the stripping procedure. Because the levels of
p20C/EBP/3 protein in the transgenic cultures of the anti-C/EBP/3 blots were similar to the
amount ofp20C/EBP/3 protein in the transgenic cultures of the anti-FLAG blots, it seems
reasonable to conclude that the p20C/EBP/3 seen in the anti-C/EBP/3 blots represent the
transgene. This is further reinforced by the lack of evidence of endogenous p20C/EBP/3
protein in the wild-type cultures.
C/EBP Beta
A variety ofwestern blots from different experiments were probed with anti-
C/EBP/3 to display all endogenous isoforms of C/EBP/3 plus the FLAG-tagged transgenic
p20C/EBP/3. The results varied with the majority of the blots showing the presence of the
endogenous full-length p35C/EBP/3 in both the wild-type and transgenic lanes. What
differed, however, was the amount of the p20C/EBP/3 proteins present in the wild-type vs
transgenic lanes. The FLAG-tagged p20C/EBP/3, hereafter referred to as FLp20C/EBP/3,
is 8 amino acids larger than the endogenous p20C/EBP/3 and should mn at a molecular
weight of about 20.8kD. It was difficult differentiating between the endogenous and
transgenic FLp20C/EBP/3 in the transgenic lanes because over-expression of the
transgene resulted in overlap of the bands that were so close in proximity to each other.
The masking of endogenous p20C/EBP/3 in the transgenic lanes made it impossible to
determine the effects the transgene had on endogenous p20C/EBP/3 protein levels. The
transgenic lanes consistently showed the presence ofp20C/EBP/3 protein, comprised of
both endogenous and transgenic FLp20C/EBP/3. In general, the WT lanes, representing
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only endogenous p20C/EBP/3, revealed protein to be present in about half of the blots
probed for C/EBP/3. (Figure 13,14) When present in both WT and TG lanes, the band for
the 20kD protein was consistently stronger in the transgenic lanes, revealing the presence
of the transgene in addition to endogenous p20C/EBP/3 protein normally present in wild-
type cultures. When endogenous p20C/EBP/ protein was undetectable in the wild-type
lanes, it is believed that the 20kD bands present in the transgenic lanes was transgenic
FLp20C/EBP/3. (Figure 13) It is important to note that earlier experiments that failed to
detect endogenous C/EBP/3 isoforms were most likely due to sensitivity issues. Only the
highest expressed protein, the FLp20C/EBP/3, was visible on these blots. As experimental
techniques were refined, all endogenous isoforms of C/EBP/3 could be seen in these later
experiments.
When observing the individual levels of endogenous p35C/EBP/3 proteins in the
wild-type lanes it was noted that there were no consistent changes in the levels
throughout the different time-points as osteoblast differentiation was proceeding. This
can be appreciated by looking at the tubulin normalization controls. (Figure 14) This was
also the case for the levels of endogenous p35C/EBP/3 proteins in the transgenic lanes
throughout the time-points. These time-points covered a range from day 7 to day 28
extracts, from the time of rapid cell proliferation to a highly differentiated osteoblast
culture. There also did not seem to be a great difference in the level of endogenous
p35C/EBP/3 proteins between the wild-type and transgenic lanes at each individual time-
point, suggesting that transgenic over-expression ofp20C/EBP/3 did not alter endogenous
C/EBP/3 expression levels. (Figure 14) Overall, there was not a great deal of variation
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throughout the levels ofp35C/EBP/3 proteins between wild-type and transgenic lanes
throughout the various time-points. (Figure 14)
The levels of endogenous p20C/EBP/3 proteins in the wild-type lanes appeared
stable throughout the time-points as osteoblast differentiation was proceeding. The
amount ofp20C/EBP/3 protein seen in the transgenic lanes appeared to be 5-10 fold
higher than that seen expressed in the wild-type cultures. (Figure 14, 16) It is important to
remember that we are seeing both endogenous and the overexpressed transgenic
FLp20C/EBP/3 in the transgenic lanes, and that it is difficult to differentiate between the
two. It was interesting to note that the levels ofp20C/EBP/3 proteins present in the
transgenic lanes seemed to vary over time in different experiments. Some blots revealed
the levels ofp20C/EBP/3 proteins in the transgenic lanes decreasing over the time-points
(Figure 13, 15) similar to the way anti-FLAG blots revealed decreasing expression of
FLp20C/EBP/3 over the time-points. (Figure 11) Others showed that the levels of
proteins remained relatively stable throughout the transgenic time-points. (Figure 14, 16)
Furthermore, some even revealed an increase in the levels ofp20C/EBP/3 proteins in the
transgenic lanes over the time-points. (Figure 17) This experiment showed low apparent
expression ofFLp20C/EBP/3 at day 7 relative to day 14 and 21. The low tubulin signal
for this lane of day 7 suggests either a possible under-loading ofprotein or a transfer
artifact. Because it was anticipated that there was a transfer artifact visible in the original
blot at 50Kd where tubulin should be, (Figure 17) this experiment was repeated using
anti-FLAG. This parallel experiment showing equal loading ofprotein illustrated that
while the levels ofp20C/EBP/3 proteins in the transgenic lanes were higher at day 14 and
21, they were not evident at day 7. (Figure 18) This strengthens the earlier claim of an
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increase in levels ofp20C/EBP/3 proteins at day 14 and 21 in the transgenic lanes but
with caution because anti-FLAG showed evidence ofFLp20C/EBP/3 only while anti-
C/EBP/3 include both transgenic and endogenous p20C/EBP/3. What this experiment did
reveal was that the transgene was not evident in this particular experiment by day 7. It
was concluded based on several experiments that the transgene protein expression
seemed to begin between day 7 and day 10 of culture. The variability seen in the levels of
p20C/EBP/3 proteins expressed in the transgenic lanes suggests inherent variability
between primary calvarial cell preparations, culture conditions, or the preparation of
whole cell extracts.
Another difference noted when observing the western blots probed with C/EBP/3
were the ratios ofp35 versus p20C/EBP/3 between the wild-type and transgenic lanes.
(Figure 14) The significance of these ratios is that ifmore p35 than p20C/EBP/3 exists,
more trans-active, full-length C/EBP/3 is present during osteoblast differentiation. If
higher levels ofp20 vs p35C/EBP/3 exist then terminal osteoblast differentiation could be
inhibited by the presence of the dominant negative p20C/EBP/3 isoform. It was important
to see if the ratio of endogenous p35 to p20C/EBP/3 in the wild-type cultures changed
during osteoblast differentiation, signifying regulation of endogenous C/EBP activity. In
some experiments, the wild-type cultures showed the levels of endogenous p35 proteins
to be higher than the levels ofp20C/EBP/3 proteins present at each time-point. (Figure
14) In other experiments, the wild-type cultures showed the levels of endogenous p35
proteins to be similar or slightly less than the levels ofp20C/EBP/3 proteins present at
each time-point. (Figure 16) Although the ratio ofp35 to p20C/EBP/3 in the wild-type
cultures seemed to be variable from experiment to experiment, this ratio throughout the
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wild-type time-points was seen to be stable within each experiment. This stable ratio
indicates that the levels of endogenous C/EBP proteins are not altered during osteoblast
differentiation. This is important because changes in the ratio ofp35 to p20C/EBP/3
would likely be associated with altered C/EBP transcription activity, which in turn might
have effects on osteoblast gene expression. When looking at the transgenic cultures, it is
revealed that consistently higher levels ofp20 versus p35C/EBP/3 proteins are present.
(Figure 14, 16) This was expected, and is due to the overexpression of the FLp20C/EBP/3
transgene. When looking individually at the ratio ofp35 to p20C/EBP/3 throughout the
various time-points in transgenic cultures, no consistent difference was noted between
them. It is important to note that the amount ofp20C/EBP/3 protein in the transgenic vs
wild-type cultures was 5-10 fold higher. This over-expression of transgenic
FLp20C/EBP/3 is likely decreasing C/EBP transcriptional activity during osteoblast
differentiation since p20C/EBP/3 is a dominant negative inhibitor of C/EBP function.
This may explain the osteopenia seen in these transgenic mice.
Another interesting observation in western blots probed for C/EBP/3 was the
presence of degradation products seen in the transgenic lanes only. (Figure 16) It seems
likely that the p20C/EBP/3 transgene may have been unstable during the extraction
procedures, thereby creating degradation products visible in the western blots. These
degradation products were completely lacking in the wild-type lanes, including those
lanes that contain endogenous p20C/EBP/3 proteins. (Figure 14) This tells us that the
degradation products were likely to be degradation products of the transgene. It is
possible that endogenous C/EBP proteins may also have generated degradation products
in amounts too low to be detected by western blot analysis.
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An alternative method for extraction ofprimary cells in culture was performed
using NE-PER Pierce Kit. These extracts generated both cytoplasmic and nuclear extracts
in order to provide insight into the location of the transgene. It appears that the p20
transgene was restricted to the nucleus because there is no evidence of the transgene in
the cytoplasmic fractions (Figure 19). In addition, there was evidence for C/EBP/3
degradation under the nuclear extraction conditions, where a 14Kda protein was seen in
the transgenic cells only (Figure 20, 21). The levels ofp35C/EBP/3 were similar in both
the wild-type and transgenic lanes at day 14 in both the cytoplasmic and nuclear extracts.
In the cytoplasmic extracts, the levels ofp35C/EBP/3 in the transgenic cells appeared to
decrease from day 14 to 21. This same decrease in p35C/EBP/3 was not observed in
nuclear extracts from transgenic cells. One experiment showed that the levels of
p38C/EBP/3 were similar for the wild-type and transgenic animals at day 14 in both the
cytoplasmic and nuclear extracts. These levels ofp38C/EBP/3 appeared to drop off at day
21 in the transgenic cells in both the cytoplasmic and nuclear extracts. Unfortunately, for
technical reasons, day 21 extracts from the wild-type cells were unavailable for
comparison. In a different experiment, the levels ofp38C/EBP/3 were similar in both the
wild-type and transgenic day 14 cytoplasmic extracts. This was not the case in the
nuclear day 14 extracts where the levels p38C/EBP/3 were higher in the transgenic than
wild-type lanes (Figure 21). It can be appreciated from the tubulin loading control
reprobes that tubulin is a cytoskeletal protein that is mostly present in the cytoplasm. This
explains why higher amounts of tubulin were observed in the cytoplasmic extracts even
though equal amounts of total protein were loaded into both. (Figure 21)
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C/EBP Alpha
C/EBPa exists in two isoforms, 30kD and 42kD, due to alternative use of
translation initiation codons in the mRNA molecule. In adipocytes, C/EBPa is known to
be anti-proliferative, signaling pre-adipocytes to exit the cell cycle and undergo terminal
differentiation.[27] It has been suggested that the 42kD isoform is the more anti-
proliferative isoform while the 30kD isoform promotes differentiation. Both isoforms
were visible on the anti-C/EBPa blots and it is apparent that there were no major
differences between the wild-type and transgenic lanes at each time point for each
isoform. (Figure 22) The similar levels of expression between the wild-type and
transgenic lines at each time point also indicates that overexpression ofFLp20C/EBP/
did not regulate C/EBPa expression. It was noted, after normalization to the tubulin
loading controls, that stable levels of C/EBPa expression (Figure 22) were present from
day 14 to day 28, corresponding to the timing ofterminal osteoblast differentiation.
C/EBP Delta
The C/EBP6 protein, using antibody from Santa Cruz Biotechnology, Inc., ran at
about 36kD and was detectable in all experiments, along with several non-specific bands.
The amount of C/EBP6 protein expressed did not vary substantially between the wild-
type and transgenic mice at each time point. (Figure 23) It was also noted, based on the
tubulin normalization controls, that stable levels of C/EBP6 expression were present from
day 14 to day 28 (Figure 23). In a second experiment, following days 7 through day 21
(Figure 24), an artifact was present in the tubulin loading control for day 21 of the WT
and TG lanes. This artifactually increased the levels of C/EBP6 at day 21 which, by the
previous experiment, seemed to be stable throughout osteoblast differentiation.
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Runx2
Runx2 has been reported to mn at a molecular weight of45kD, 60kD and 65kD
on western blots. [28] It can be seen that only the presence of the full-length 65kD Runx2
protein was present in the blots probed for Runx2. (Figure 25) Although there was an
immunoreactive protein present just below 45kD, it seems unlikely that this represents
the previously reported 45kD Runx2 protein because its apparent molecular weight is too
low. This may be a non-specific band or a possible degradation product of a higher
molecular weight isoform. Focusing on the presence of the 65kD Runx2 protein, it is
evident that no clear differences were seen between the amount ofRunx2 expressed in
wild-type and transgenic cells at each of the individual time points. Also there appeared
to be stable levels ofRunx2 expression from day 7 to day 21 (Figure 25) corresponding
to the timing ofboth osteoblast proliferation and differentiation, respectively.
ATF4
ATF-4, which is also known as CREB-2, has a predicted molecular weight of
38kD. ATF4 is a heavily phosphorylated protein that has been shown in the literature to
mn as a doublet. This pattern of expression was observed in the immunoblots probed for
ATF4, with the lowest band corresponding to the 38kD protein. (Figure 26)
There was a tendency for decreased ATF4 expression late in transgenic cultures at day 17
and 21. This observation needs to be interpreted cautiously because, for technical
reasons, we were unable to obtain a reliable tubulin loading control for normalization
purposes. It will be important to perform additional experiments with appropriate




In primary calvarial cell cultures, it has been shown that osteoblastic cells first
undergo a phase ofproliferation that starts at day 1 and ends around day 14. There exists
a burst, or an increase in proliferation, that occurs mainly between day 6 and day 12. At
day 14, the cells taper the rate ofproliferation and enter the next phase, termed
differentiation. It is during days 14 to day 28 that these cells undergo differentiation and
become mature osteoblasts. The time points studied through these experiments ranged
from day 7 to day 28, including both proliferation and differentiation along the osteoblast
differentiation pathway. The bone extracellular matrix macromolecules or "markers" that
are normally expressed in the early stages of the osteoblast lineage include osteopontin,
CollA1 and alkaline phosphatase.[29] The mid-stage of differentiation corresponds to an
expression ofbone sialoprotein while terminal markers of osteoblast differentiation
include expression of osteocalcin and the transgenic reporter pOBCol2.3 GFP.[29]
Recent work in our lab found that at the cellular level the p20C/EBP/3 transgene interferes
with terminal osteoblast differentiation or differentiated function.[30] An increase in
bone sialoprotein expression was seen, coupled with a reduction in osteocalcin mRNA,
raising the possibility that there is a differentiation bottleneck and an accumulation of
cells expressing a pre-osteoblastic phenotype. [30]
Experiments performed in the primary calvarial cell cultures showed pOBCol
2.3GFP fluorescent expression to initiate around days 7 to 10 in the wild-type cultures
and around day 12-14 in the transgenic cultures. It was noted that the formation of
osteogenic nodules in both wild-type and transgenic wells began around day 14. It was
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consistently observed that although the number of transgenic colonies ultimately
exhibiting GFP expression between wild-type and transgenic cultures was similar, both
the intensity of GFP expression and the amount of mineralization in transgenic cultures
were decreased at coincident time points. This indicates that osteoblastic differentiation
or function is inhibited in transgenic cell cultures. These results support similar data
found previously in our laboratory using stromal cell cultures.
To follow the expression of the p20C/EBP/3 transgene in cells of the osteoblast
lineage, an amino-terminal FLAG epitope was incorporated into the p20C/EBP/3
construct. The blots probed for anti-FLAG demonstrated the presence of our transgene
corresponding to the 20kDa proteins in the transgenic lanes only. As expected, there was
no immunoreactivity seen in the wild-type lanes at 20kDa, serving as a negative control
for the presence of our transgene. Although unexpected, the general trend throughout the
blots was that FLAG-tagged p20C/EBP/3 protein, once expressed, decreased over time in
culture, pOBcol3.6GFP, which is driven by the same promoter as the transgene, comes
on early in the osteoblast lineage and stays equally present throughout terminal osteoblast
differentiation, pOBcol3.6GFP is expressed around day 7 at the multi-potential precursor
stage of the cultures 1] and our experiments showed FLAG to appear at a similar time
frame, between days 7 and 10. The anti-FLAG blots stripped and probed for anti-C/EBP/3
showed similar levels ofp20C/EBP/3 protein in the transgenic lanes as compared to the
amounts ofFLAG-tagged protein. The levels ofprotein also seemed to decrease
progressively over time as they did in the anti-FLAG blots. Unfortunately, due to
possible sensitivity issues, there was no evidence of endogenous p20C/EBP/3 in the wild-
type cultures upon stripping and re-probing, and the levels of endogenous full-length
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C/EBP/3 were not easily visible. The FLAG-tagged p20C/EBP/3 is 8 amino acids longer
than the endogenous p20C/EBP/3 and should run at a molecular weight of about 20.8kD.
It was difficult to differentiate between the endogenous and transgenic FLp20C/EBP/3 in
the transgenic lanes because the strong overexpression of the transgene resulted in
masking ofthe endogenous p20C/EBP/3 band. Because the levels ofp20C/EBP/3 protein
in the transgenic samples probed with anti-C/EBP/3 were similar to the amount of
p20C/EBP/3 protein in the transgenic samples probed with anti-FLAG, it seems
reasonable to conclude that the vast majority of the p20C/EBP/3 seen in the anti-C/EBP/3
blots represent the transgene. This is further reinforced by the lack of evidence of
endogenous p20C/EBP/3 protein in the wild-type cultures.
It has been demonstrated that C/EBP transcription factors support osteoblast-
specific gene expression and may play an important regulatory role during osteoblast
differentiation.[5] It has been found that C/EBP/3 and C/EBP6 are expressed in skeletal
tissues and are developmentally regulated during osteoblast maturation.J5] In primary rat
osteoblast cultures, Gutierrez et al. found that C/EBP/3 and C/EBP6 are abundantly
expressed in proliferating cells, decline during the mid-stage of differentiation, and then
subsequently increase at late stages of differentiation. [5] In contrast to these findings,
Iyer et al, using the murine MC3T3-E1 osteoblast model, reported that C/EBP/3 protein
levels and DNA binding activity were high in proliferating cells but decreased during
differentiation. [4] They found that constitutive expression of full length C/EBP/3
increased proliferation and prevented differentiation. Another recent study by Shin, et al.
using mouse calvarial and ostoblastic MC3T3-E1 cells found the expression of C/EBP/3
in MC3T3-E1 cells to gradually decrease during culture from day 0 to day 19. [31] Their
33
findings were analogous to those of Iyer et al.[4] who reported that the overexpression of
C/EBP/3 in MC3T3-E1 cells suppressed osteogenic differentiation, but promoted
proliferation. In the numerous western blots probed for C/EBP/3 in our studies, the
majority showed equal expression of endogenous p35C/EBP/3 in both the wild-type and
transgenic lanes at each time-point. In addition, there was not a great deal of variation in
the levels ofp35C/EBP/3 proteins between wild-type and transgenic lanes throughout the
various time-points, coveting a range from day 7 to day 28. What did differ in these
western blots was the presence ofp20C/EBP/ whose expression was consistent in the
transgenic lanes while present in only half of the blots wild-type lanes. When present in
both lanes, the band for the 20kDa protein was consistently darker in the transgenic lanes,
revealing the presence ofboth the transgene as well as the endogenous p20C/EBP/3
normally present in wild-type mice. When endogenous p20C/EBP/3 protein was
undetectable in the wild-type lanes, it is believed that the 20kD bands present in the
transgenic lanes was transgenic FLp20C/EBP/3. It is important to reiterate that earlier
experiments failed to detect endogenous C/EBP/3 isoforms due to possible sensitivity
issues. Only the highest expressed protein, the transgenic FLp20C/EBP/3, was visible on
these blots. As our experimental techniques were refined, all endogenous isoforms of
C/EBPB could be seen in later experiments. Also noted when looking at the transgenic
cultures were the varying levels ofp20C/EBP/3 proteins throughout the time-points. It is
important to remember that both endogenous and transgenic p20C/EBP/3 contribute to the
signal observed in the transgenic lanes and that it is impossible to discriminate between
them. Some blots revealed decreasing levels ofp20C/EBP/3 expression over the time-
points; others showed equal levels ofproteins, while some even revealed an increase in
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the levels ofprotein expression. In spite of our attempts to control for variables in these
experiments, the differences in protein expression seen between experiments may reflect
the inherent differences between mice from which cells are derived, between the primary
osteoblast culture preparations, or between the conditions used for cell culture or the
preparation ofwhole cell extracts.
A large difference was seen between the ratios ofp35 versus p20C/EBP/3 between
the wild-type and transgenic mice. While the levels of endogenous p35 proteins were
higher than the p20C/EBP/3 proteins in the wild-type lanes, the opposite was noted in the
transgenic lanes where consistently higher levels ofp20 versus p35C/EBP/3 proteins
existed. This was an expected finding since the transgene is being over-expressed and
was therefore present at high levels. The significance of these ratios is that more trans-
active, full-length C/EBP/3 is present during osteoblast differentiation in the wild-type
cultures while more dominant negative p20C/EBP was present in the transgenic
cultures, likely inhibiting C/EBP function and terminal osteoblast differentiation. The
ratio of endogenous p35 to p20C/EBP/3 in the wild-type cultures remained constant
during osteoblast differentiation, suggesting no regulation of C/EBP/3 levels during
differentiation. The ratio ofp20 versus p35C/EBP/3 throughout the various transgenic
time-points also seemed to remain fairly constant.
An interesting observation in the western blots probed for C/EBP/3 was the
presence of degradation products in the transgenic lanes only. Because these degradation
products are completely lacking in the wild-type lanes, their presence must be due to the
transgene which may be sensitive to degradation during the protein extraction procedures,
resulting in these degradation products. Consistent with this possibility, an
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aforementioned study demonstrated the generation of truncated C/EBP/3 isoforms via
artifactual proteolysis of full-length C/EBP/3 during preparation ofnuclear extracts.[3]
They noted that only the full length p34 and p38C/EBP/3 proteins are detected in the
cytoplasm as newly translated polypeptides while the p 14 and p20C/EBP/3 isoforms are
observed only in the nuclear extracts. Because translation occurs in the cytoplasm only, it
is suggested that the p 14 and p20C/EBP/3 isoforms arise from proteolysis and not from
alternative translation initiation. By comparing various extraction procedures they
determined that p20C/EBP/3 is generated predominantly by in vitro proteolytic cleavage
during isolation from cells and that p14C/EBP/3 is produced exclusively by this
mechanism.[3] It was also determined that C/EBP/3 must be localized to the nucleus in
order to undergo proteolytic cleavage. It appears that the primary nuclear extracts
obtained using the Pierce Kit underwent this same type of degradation. This proteolysis
was seen only in the transgenic cells, which might be a function of assay sensitivity, i.e.
only the highest expressed proteins allowed visualization of the degradation products.
Despite seeing the degradation products, the high level ofp20C/EBP/3 protein evident in
the transgenic cultures suggests nuclear localization of the transgene. This suggests that
our transgene is primarily localized in the nucleus because it was not evident in the
cytoplasmic extracts. Previous experiments in our lab using both in vivo bone and in vitro
osteoblasts have also seen evidence oftransgene protein in the nucleus only. (Figure 21)
Although it has been reported that C/EBPa was not been detected in bone by
several authors [5, 31], this was not the case in our experiments. C/EBPo exists in both
30kD and 42kD isoforms, both ofwhich were visible on the immunoblots. There was no
consistent difference between the wild-type and transgenic lanes at each time point for
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each isoform, signifying that overexpression ofFLp20C/EBP/3 did not regulate C/EBPc
expression. Stable levels of C/EBPc expression (Figure 22) were present from day 14 to
day 28, corresponding to the timing of terminal osteoblast differentiation. This suggests
that an increase in C/EBP levels is not driving terminal differentiation of the osteoblast
lineage. This is different from what is seen during adipogenesis, where there is an
increase of C/EBPc expression during the late stages of adipocyte differentiation.
C/EBPe has been demonstrated to regulate the terminal differentiation ofpreadipocytes
to adipocytes.[32] In addition, C/EBPo is also known to direct the expression of terminal
adipocyte marker genes.[ 16] The loss of C/EBPc interferes with terminal adipocyte
differentiation and differentiated function of the adipocytes.[ 17] Due to the stable levels
of C/EBPc expression from day 14 to day 28, it seems reasonable to conclude that
increased C/EBP expression does not account for terminal osteoblast differentiation, as
it does in adipocyte differentiation. However, the presence of C/EBPc in primary
osteoblast cultures suggests that it may still play an important role in osteoblast
differentiation or function.
It has been reported that Runx2, a transcription factor essential for osteogenesis, is
an important direct regulator of C/EBP6 expression in osteoblasts by way of a Runx
binding sequence located in the C/EBP6 gene promoter. [33] C/EBP6 has been found to
enhance mouse osteocalcin gene expression through synergistic cooperation with Runx2.
[31] These links to Runx2 and osteogenesis demonstrate the importance of C/EBP6 in
osteoblast differentiation given that Runx2 is essential for osteoblast responses to
extracellular matrix signals and required for the expression of genes associated with
osteoblast differentiation. Although the predicted gene sequence ofmurine C/EBP6
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predicts a molecular weight of 29kD, a study [34] on primary osteoblast cell cultures of
Sprague-Dawley rats showed C/EBP6 to have an apparent molecular weight of around
36kD, the same as we observed in our experiments. These primary osteoblast cell
cultures were prepared from the parietal bones of Sprague-Dawley rats in a similar
manner as our murine primary calvarial cell cultures. In addition, this study used the
same antibodies to C/EBP6 (Santa Cruz Biotechnology, Inc.) that we used in our western
blot experiments. Another very recent study by Shin, et al. [31] studying primary
calvarial mouse osteoblasts demonstrated the presence of C/EBP6 on their western blots
around 33kD. These studies show the murine C/EBP6 protein to exhibit an apparent
molecular weight somewhat larger than the expected 29kD. Our western blots probed for
C/EBP6 showed an immunoreactive band at a molecular weight of about 36kD. As for
C/EBP6, no differences were seen in C/EBP6 levels between the wild-type and transgenic
mice at any time point, demonstrating that overexpression ofFLp20C/EBP/3 did not
regulate C/EBP6 expression. It was also noted, after normalization to tubulin controls,
that stable levels of C/EBP6 expression were present throughout osteoblast
differentiation. A recent study by Shin, et al. using mouse calvarial and osteoblastic
MC3T3-E1 cells determined the expression of C/EBP6 mRNA to show a biphasic
pattern.[31 The expression of C/EBP6 was downregulated after cells reached
confluency, then increased during the later stage ofmaturation when osteocalcin
expression is maximal in mouse osteoblastic cell lines.[31] This maximal osteocalcin
mRNA expression was observed to occur at day 19 in this study. Our immunoblots, on
the other hand, showed relatively stable levels of C/EBP6 expression throughout all
stages of osteoblast differentiation. Our experiments did not include days 0 through 6 of
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cell culture which may have displayed increased expression of C/EBP6 as it did in days 0
and 3 of the MC3T3-E1 cultures.[31]
As mentioned above, Runx2 is a rant domain-containing transcription factor that
is essential for osteoblast differentiation and bone formation during embryogenesis and
postnatal life. The tissue specific expression and transcriptional control of osteocalcin, a
vital noncollagenous protein composing 15% ofmature bone[35], is regulated mainly by
Runx2. [8, 36] Runx2-deficient mice die at birth and lack both skeletal ossification and
mature osteoblasts. Runx2 haploinsufficiency causes the skeletal disorder cleidocranial
dysplasia, a disease characterized by defective endochondreal and intramembranous bone
formation.[7] The importance ofRunx2 in osteoblast differentiation and bone formation
is well established and it is well documented that Runx2 can interact with a number of
factors. Because Runx2 can interact with C/EBP, it is important to establish if there are
any differences in the levels ofRunx2 expression during osteoblast differentiation
between the wild-type and transgenic mice. Only the presence of the full-length 65kD
Runx2 protein was present in the blots probed for Runx2. There was no difference
between the amount ofRunx2 expressed between the wild-type and transgenic cultures at
each of the individual time points, indicating that overexpression ofFLp20C/EBP/3 did
not regulate Runx2 expression. Additionally, stable levels ofRunx2 expression was seen
from day 7 to day 21, corresponding to the timing ofboth osteoblast proliferation and
differentiation. Although it seems expected that the expression ofRunx2 would increase
during the later stages of osteoblast differentiation, corresponding to day 14 to day 28,
this was not what was actually observed. A recent study by Shin et al. noted that although
Runx2 is an essential transcription factor for osteoblast differentiation and the synthesis
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of osteoblast-specific proteins, its abundance is downregulated during osteoblast
maturation when osteocalcin expression is upregulated.[31] These authors showed that
Runx2 mRNA gradually increased from day 0 to day 12, then decreased by day 19.
Levels ofRunx2 protein expression in our studies remained stable from day 7, the early
stages of osteoblast commitment and differentiation, to day 21, corresponding with
terminal osteoblast differentitation. Once again, our experiments did not include very
early time points and may have missed the increase in Runx2 expression during the stage
of osteoblast proliferation.
ATF4, also known as activating transcription factor 4 and CREB2, is a basic
leucine-zipper transcription factor that is a member ofthe ATF/CREB protein family. An
in vivo role for ATF4 in bone development was recently described using ATF4-deficient
mice. Skeletal preparations ofATF4-/- animals showed a marked reduction or delay in
mineralization ofbones including frontal and parietal bones, clavicles and long bones.
[12] Postnatally, ATF4-deficient mice have a severe reduction in bone volume and in the
number and thickness of trabeculae that persists throughout life. In addition, the
expression ofboth bone sialoprotein and osteocalcin, markers for terminally
differentiated osteoblasts, are markedly reduced in ATF4-deficient osteoblasts. It has also
recently been determined that ATF4 and Runx2 form functional complexes with each
other and cooperatively regulate osteocalcin mRNA transcription. 12] Because both
ATF4 and Runx2 are expressed in osteoblasts, it has been suggested that ATF4 plays a
critical role in the regulation of endogenous Runx2 activity and, thereby, osteoblast
differentiation and bone formation during development and after birth. An interesting
finding is that although ATF4 mRNA is ubiquitously expressed, ATF4 protein is only
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expressed in osteoblasts. This tissue specificity is explained by proteasome-mediated
degradation ofATF4 in non-bone cells. For reasons unknown, this degradation pathway
is less active in osteoblasts allowing ATF4 accumulation. Western blots probed for ATF4
in our studies did in fact show evidence of the protein in the primary calvarial
osteoblastic cells. There seemed to be a tendency for a decrease in ATF4 expression late
at day 17 and 21 in the TG cultures. We need to be cautious when interpreting this
finding because we were unable to obtain a tubulin loading control for normalization
purposes. It is imperative that we follow up with additional ATF4 experiments to obtain
appropriate normalization to determine if this apparent decrease at day 17 and 21 in the
TG cultures is reproducible. However, if this observation is confirmed, a loss ofATF4
protein expression in transgenic cells could explain the decrease in bone formation seen
in the p20C/EBP/3 transgenic mouse model.
Conclusion
The osteoblast is the only cell type responsible for extracellular matrix deposition
in bone. Bone formation is a physiological process involved in skeletal growth, bone
remodeling and fracture repair. Diseases affecting bone formation are common and often
debilitating, underscoring the importance ofunderstanding the molecular basis of
osteoblast-specific gene expression and osteoblast differentiation. It is likely that cell
differentiation along the osteoblast lineage is controlled at least partly by cell-specific
transcription factors, such as C/EBP. Identifying these factors will be necessary to
understand diseases ofbone and for designing effective anabolic therapeutic strategies.
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FLp20C/EBP/3 contains the C-terminal basic leucine zipper domain but lacks the N-
terminal transactivation domain and therefore functions as a transcriptional repressor.
Because most members ofthe C/EBP family bind to the same or very similar recognition
sequences and are capable ofheterodimerizing with each other, p20C/EBP/3 acts as a
dominant negative regulator of C/EBP function. It was believed that compensatory
changes might be seen in the levels of C/EBP expression due to the presence of the
p20C/EBP/3 transgene. This would result in increased levels of C/EBP cells to
compensate for the C/EBP whose function has been blocked by the transgene. This does
not seem to be the case since we did not see a difference between the wild-type and
transgenic lines for the various C/EBP proteins, including C/EBP/3, and 6. This
suggests that the function of C/EBP required for osteoblast differentiation is independent
of C/EBP protein levels. The only significant difference seen between the wild-type and
transgenic cultures was the 5-10 fold increase in the levels of transgenic p20C/EBP/3
protein due to over-expression ofFLp20C/EBP/3. This resulted in a 5-10 fold decrease in
p35 to p20C/EBP/3 ratio, which should lead to a strong dominant negative inhibition of
C/EBP function. It was also observed that the levels of these endogenous C/EBP proteins
remained relatively stable in the WT culures throughout osteoblast differentiation. As
expected, Runx2 and ATF4 proteins were both expressed in primary osteoblastic
cultures. No differences were detected between the amount ofthese proteins expressed
between the wild-type and transgenic cultures at any time point, suggesting that
FLp20C/EBP/3 over-expression did not regulate the levels of these proteins. Although
there was a tendency for ATF4 expression to be reduced late in the transgenic cultures,
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this will need to be reconfirmed with future studies using an appropriate normalization
control.
If the function of C/EBP transcription factors required for osteoblast
differentiation is independent of changes in C/EBP protein levels, then how does C/EBP
promote osteoblast differentiation? It appears likely that constitutive C/EBP expression
and activity is required for normal osteoblast differentiation. Moreover, it is possible that
post-translational modification, e.g. phosphorylation, of these C/EBP proteins may
modulate C/EBP activity in a manner essential for osteoblast differentiation.
Alternatively, although the levels of C/EBP proteins remain stable throughout
differentiation, they may be interacting with other molecular partners that have been seen
to play an essential role in osteoblast differentiation such as Runx2 and ATF4. Indeed,
C/EBP/3 has been shown to be capable of direct protein-protein interactions with both
Runx2 and ATF4 [37] transcription factors.
It was evident from the Col2.3GFP fluorescent colonies that both the intensity of
GFP expression and the amount ofmineralization in transgenic cultures were decreased
at coincident time points. This demonstrates that osteoblastic differentiation or function
was hindered by the presence of our transgene. It will be important to identify molecular
targets ofp20C/EBP/3 that are involved in the inhibition of osteoblast differentiation in
these transgenic mice. Further studies should be aimed at identifying the dimerization
partners and/or other physically interacting proteins via electrophoretic mobility shift
assay and co-immunoprecipitation. These studies, by identifying molecular targets, will





Figure 1" Osteoblast Differentiation Pattern Developmental time course of osteogenic
marker expression. Osteoblasts express distinct bone extracellular matrix
macromolecules which serve as markers as they undergo the process of differentiation.
Figure 2: Marrow Derived Mesenchymal Stem Cells Osteoblast precursors are
recruited from a multipotential mesenchymal progenitor that can give rise to several
differentiated cell phenotypes including myoblasts, chondrocytes, adipocytes and
osteoblasts.
Figure 3" The Lifecycle of an Osteoblast This figure represents the lifecycle of an
osteoblast from mesenchymal stem cell to an osteocyte.
Figure 4: COOH-Terminal Dimerization Interface termed the Leucine Zipper
Segment The terminal leucine zipper mediates dimerization between C/EBP
polypeptides. This dimerization is required for DNA binding and for the activation of
transcription in target genes.
Figure 5" The Molecular Structure of C/EBPB Messenger RNA
There exist three isoforms of C/EBPI3. The p38 and p35 are the full-length isoforms
which include the transcriptional activation domain. The p20 isoform is a truncated form
which acts as a dominant/negative regulator of C/EBP function. These isoforms arise by
differential translation of C/EBPI3 mRNA.
Figure 6" Amino Terminal FLAG Epitope Incorporated into the Truncated
p20C/EBP Construct The transgenic model limits mortality of the mice by using a
specific construct to target the transgene to limited distribution within the tissues. The
pOBCol3.6 construct utilizes the Co13.6 fragment of the Collal promoter that is
preferentially expressed in bone, teeth, skin, tendon and lung. To identify the cells that
express this C/EBP transgene, an amino-terminal FLAG epitope is incorporated into the
p20C/EBP construct.
Figure 7" BCA Protein Assay Curve A BCA protein assay is performed to determine
the amount ofprotein present in the primary extract samples. The plate reader reads the
samples at an absorbance of490 nanometers and creates a curve fit report with a formula
for the curve, the slope and the intercept. It is from this curve that the amount ofprotein,
in micrograms, is derived.
Figure 8" 40X Phase and GFP Expression in 6-well Plates Phase contrast and
fluorescence (GFP) microscopy to measure osteoblast differentiation in wild-type and
transgenic primary calvarial cells grown in 6-well plates at the indicated time points.
Figure 9" 100X Phase and GFP Expression in 6-well Plates Phase contrast and
fluorescence (GFP) microscopy to measure osteoblast differentiation in wild-type and
transgenic primary calvarial cells grown in 6-well plates at the indicated time points.
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Figure 10: Fluorimaging in 6-well Plates Expression of GFP was visualized by
fluorimaging at indicated time points in primary calvarial cells from both wild-type and
transgenic mice.
Figure 11" Anti-FLAG Immunoblot Bands at 20kD in the TG lanes indicate the
presence of the FLAG-tagged p20C/EBP transgene with no immunoreactivity in the WT
lanes serving as a negative control.
Figure 12: Stripping Anti-FLAG Immunoblot and Reprobing for C/EBP/ Due to
reduced sensitivity, only the highly expressed FLp20C/EBP transgene is detected.
Figure 13" Western Blot Probed for C/EBPfl Evidence of endogenous p35C/EBP in
both WT and TG lanes while p20C/EBP/ present only in the transgenic lanes, indicating
the presence ofthe transgene.
Figure 14: C/EBPfl Protein Expression Strong overexpression of the transgene masking
endogenous levels ofp20C/EBP/ in the TG lanes, along with degradation products in
these lanes. Stable levels of endogenous p35 and p20 seen in WT lanes throughout
osteoblast differentiation. Six-fold.decrease in p35:p20ratio in the TG cultures which
would be associated with a strong dominant negative inhibition of C/EBP function.
Figure 15" Anti-C/EBP/ Immunoblot This was one of the earlier experiments in which
sensitivity was limited showing only the most highly expressed protein, the
overexpressed FLp20C/EBP/3 transgene.
Figure 16" Western Blot Probed for C/EBP Over-expression oftransgene masking
endogenous p20C/EBP/ along with degradation products in the TG lanes. Endogenous
p35 and p20 in WT lanes relatively stable throughout osteoblast differentiation. Ten-fold
decrease in p35 :p20ratio in the TG cultures which would be associated with a strong
dominant negative inhibition of CEBP function. No compensatory changes in
endogenous p35 in TG lanes due to FLp20C/EBP/ transgene overexpression. Note the
artifact ofunknown origin present in TG lane at day 21, which was not seen in other
experiments.
Figure 17: Time Course of Transgene Expression in C/EBP/ Immunoblot This
experiment showed low apparent expression of the p20 at day 7 relative to day 14 and 21.
The low tubulin signal for this lane on day 7 suggests either a possible under-loading of
protein or a transfer artifact. Because it was anticipated that there was a transfer artifact
visible in the original blot at 50Kd where tubulin should be, this experiment was repeated
with a fresh blot for FLAG to see if the TG was expressed on day 7.
Figure 18" Western Blot Probed for FLAG Showing no evidence of the FLp20C/EBP
transgene at day 7 of culture.
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Figure 19" Cytoplasmic C/EBP Expression Although p35C/EBP/ was present in both
WT and TG lanes, there was no evidence ofp20C/EBP proteins in either lane,
suggesting that the FLp20C/EBP transgene is efficiently translocated to the nucleus.
Figure 20: Nuclear C/EBP Expression FLp20C/EBP transgene was restricted to the
nucleus and underwent degradation probably during the nuclear extraction process.
Smaller C/EBP protein isoforms were seen around 11KD in the TG lanes only.
Figure 21" Cytoplasmic and Nuclear C/EBP proteins on a single blot. Evidence of
the FLp20C/EBP transgene in the nuclear extracts only, indicating nuclear localization
of the transgene. Degradation products are seen in the TG lanes only.
Figure 22" C/EBPo Expression During Osteoblast Differentiation C/EBP exists in
two isoforms, 30 and 42kD isoforms, both ofwhich were visible on the blots at all time
points.
Figure 23" Immunoblot Probed for C/EBPJ C/EBP present at around 36kD with
expression levels relatively stable throughout the time course of osteoblast
differentiation.
Figure 24" Western Blot Probed for C/EBPi Expression levels were stable during
osteoblast differentiation. While it appears that expression seems to be increasing at day
21 in the cultures, an artifact in the tubulin normalization control artifactually increased
normalized expression levels.
Figure 25" Runx2 Expresssion Runx2 is seen at a molecular weight of 65kD. There was
no dramatic difference between the levels present in the WT and TG cultures at any time
point .Stable levels of endogenous expression seen throughout differentiation.
Figure 26:ATF4 Expression ATF4 is a 38kd protein that is heavily phosphorylated and
tends to run as a doublet. There seems to be a tendency for a decrease in ATF4
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